The healthcare industry has faced a flurry of sweeping changes at the federal level since President Donald Trump took office. In recent months, healthcare leaders have scrambled to come up with ...

The Trump administration’s crackdown on fraud, waste and abuse continues, with the Department of Justice last week launching a new effort targeting healthcare fraud. Experts think the new strike force ...

Severe asthma is already treatable with a monthly injectable GSK drug, the blockbuster product Nucala. A new FDA approval gives the drugmaker the opportunity to reach patients with a different ...

Rosarium Health, a company enabling aging at home, has raised $6 million in seed funding and secured partnerships with several Medicaid and Medicare Advantage plans, the company shared with MedCity ...

Disagreements between providers and payers have been moving into the courtroom over the past few weeks. The California ...

Tennessee lawmakers recently passed a bill banning PBMs from owning pharmacies in the state, though like a similar Arkansas ...

Bayer is paying $300 million to buy Perfuse Therapeutics, a clinical-stage biotech that offers a new growth opportunity in ophthalmology as the pharmaceutical company’s top eye product weathers ...

April has seen a slew of executive hires, promotions and layoffs across the healthcare industry. For instance, Aledade, ...

UCB is adding a big piece to its immunology pipeline with a multi-billion dollar deal to buy Candid Therapeutics, a clinical-stage biotech company developing therapies in a promising but competitive ...

Two North Carolina-based health systems, Atrium Health and WakeMed Health, announced plans to merge last week. As part of the proposed deal, Atrium plans to invest $2 billion into WakeMed and create 3 ...

Healthcare is the most expensive line item in every household in America, followed by housing, transportation, education and groceries, according to Mark Bertolini, CEO of Oscar Health. However, ...

Patients who switched from weekly to monthly maintenance dosing of an experimental Pfizer obesity drug achieved an average placebo-adjusted weight loss of up to 12.3% in a mid-stage study, results ...